Plantar Wart Clinical Trial
Official title:
Intralesional Injection of Bleomycin Versus 5-fluorouracil in Treatment of Plantar Wart; a Comparative Study
Group 1; intralesional injection of bleomycin in plantar wart. Group 2; intralesional injection of 5-fluorouracil in plantar wart
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | September 1, 2022 |
Est. primary completion date | March 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: Subjects must meet all of the following criteria to be considered for participation in this study. 1. Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study. 2. Male or female = 8 years old. 3. Subject has a clinical diagnosis of common warts. 4. Subject has up to 1 Target Wart and up to 3 additional Non-Target Warts located on the trunk or extremities. The identified Target and Non-Target Warts must meet the requirements as defined below: 1. Each wart must have a longest axis that is = 3mm and = 8 mm and have a thickness of =3mm 2. Each wart must be a discrete lesion 3. Each wart must be present for at least 4 weeks 4. Not be covered with hair which, in the investigator's opinion, would interfere with the study medication treatment or the study evaluations 5. Not be in an intertriginous fold 6. Be the only common wart present when the circular cutout template is centered over the wart 5. The Target and Non-Target Warts must have a PWA = 2. 6. Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization. 7. Woman of childbearing potential (WOCBP) must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study. 8. Subject is non-pregnant and non-lactating. 9. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target or Non-Target Warts or which exposes the subject to an unacceptable risk by study participation. 10. Subject is willing and able to follow all study instructions and to attend all study visits. Exclusion Criteria: Subjects are excluded from this study if any 1 or more of the following criteria is met: 1. Subject has clinically atypical warts on the trunk or extremities. 2. Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant |
Country | Name | City | State |
---|---|---|---|
Egypt | Sohag Faculty of Medicine | Sohag |
Lead Sponsor | Collaborator |
---|---|
Sohag University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response to intralesional injection of bleomycin, 5fluorouracil in treatment of plantar wart | Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated
Near Clear: A visible wart that is less than 3mm in maximal diameter (or length) A visible wart = 3mm and <6 mm in maximal diameter (or length) A visible wart = 6mm in maximal diameter (or length) |
3monthes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05324904 -
Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts
|
N/A | |
Completed |
NCT00328991 -
Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts
|
N/A | |
Completed |
NCT05592041 -
Studying of Natural Constituents' Treatment of Plantar Warts
|
Early Phase 1 | |
Completed |
NCT05115669 -
Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts
|
N/A | |
Recruiting |
NCT06261684 -
Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial.
|
Phase 2/Phase 3 | |
Recruiting |
NCT02151630 -
Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04823845 -
Plantar Wart Treatment Using Adapalene Gel
|
Early Phase 1 | |
Completed |
NCT05588999 -
Comparative Study Between Treatment With Cryotherapy Alone Versus Cryotherapy Plus Salicylic Acid Dressing for Planter Warts
|
Phase 1 | |
Completed |
NCT01536834 -
Safety & Performance Study of Verruca Treatment Device
|
N/A | |
Recruiting |
NCT05488860 -
Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases
|
N/A | |
Recruiting |
NCT05520658 -
Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts
|
N/A | |
Not yet recruiting |
NCT04654091 -
Cryotherapy VS. Nitric-zinc Complex in the Treatment of Plantar Warts.
|
N/A | |
Not yet recruiting |
NCT05599971 -
Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts
|
N/A | |
Not yet recruiting |
NCT05198180 -
Treatment of Plantar Warts
|
Phase 3 | |
Recruiting |
NCT06214559 -
Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.
|
N/A | |
Recruiting |
NCT03977753 -
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
|
Phase 4 | |
Completed |
NCT03183765 -
Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts
|
Phase 4 |